¹⁷⁷Lu-PSMA radioligand therapy for metastatic castration-resistant prostate cancer.
Rune SundsetHege Sagstuen HaugnesAlexander PerezOla EngelsenIda H H FosseideMiguel J CastillejoTrond Velde BogsrudPublished in: Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke (2024)
Treatment with [¹⁷⁷Lu]PSMA radioligand resulted in a temporary regression of the metastases.